Wall Street analysts expect that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post sales of $10.59 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with the highest sales estimate coming in at $13.25 million and the lowest estimate coming in at $6.68 million. Dicerna Pharmaceuticals posted sales of $1.55 million during the same quarter last year, which indicates a positive year over year growth rate of 583.2%. The firm is expected to issue its next earnings report on Monday, May 13th.

According to Zacks, analysts expect that Dicerna Pharmaceuticals will report full year sales of $42.99 million for the current year, with estimates ranging from $26.70 million to $53.80 million. For the next fiscal year, analysts anticipate that the company will post sales of $39.52 million, with estimates ranging from $15.00 million to $68.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Dicerna Pharmaceuticals had a negative return on equity of 65.91% and a negative net margin of 1,438.68%. The company had revenue of $1.54 million for the quarter, compared to analyst estimates of $8.38 million.

DRNA has been the subject of a number of recent research reports. Leerink Swann assumed coverage on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 27th. They issued an “outperform” rating and a $24.00 price objective for the company. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 25th. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, January 8th. Chardan Capital raised shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Tuesday, January 22nd. Finally, ValuEngine downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $21.78.

Hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Dicerna Pharmaceuticals by 512.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 2,894 shares during the period. Legal & General Group Plc lifted its stake in shares of Dicerna Pharmaceuticals by 38.7% in the 4th quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 2,561 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Dicerna Pharmaceuticals by 30.3% in the 4th quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 2,465 shares during the period. TD Asset Management Inc. purchased a new stake in Dicerna Pharmaceuticals during the 4th quarter worth about $169,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Dicerna Pharmaceuticals by 19.9% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 3,024 shares during the last quarter. 92.81% of the stock is currently owned by institutional investors.

Shares of DRNA stock opened at $12.91 on Thursday. The stock has a market cap of $809.87 million, a P/E ratio of -10.76 and a beta of 2.40. Dicerna Pharmaceuticals has a 52 week low of $8.71 and a 52 week high of $17.98.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Recommended Story: Percentage Decliners

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.